Parkinson School, a place of support and information

The Parkinson School offers comprehensive support and information for people with Parkinson's and their families. As one of the original main goals of the Parkinson Verbund eV, the Parkinson Journal has taken on the task of realizing this.

The result is a unique series of lectures that covers the entire spectrum of topics related to our disease. The series of lectures aims to educate participants about Parkinson's disease and to deepen their knowledge. In online lectures lasting around one hour, all essential aspects of the disease are covered in order to enable those affected to meet their therapists and neurologists on an equal footing and to deal with the disease more confidently.

Placebo effect in Parkinson’s disease

There are studies that look at the placebo effect in Parkinson's. The placebo effect plays an important role in the treatment of Parkinson's and can affect the symptoms of the disease in various ways.

What you need to know about Parkinson's

When a person with Parkinson's or a relative wants to find out about a possible disease, accompanying symptoms play a crucial role. These can affect different parts of the body, including skin, skeleton, sensory organs and psyche. The severity and occurrence of these symptoms vary from person to person, and it is important to note that some symptoms may have other causes.

Produodopa. The new medication standard?

However, the  perspectives changed fundamentally with the introduction of Produodopa®, a subcutaneous infusion solution. Continuous infusion over 24 hours using a portable pump ensures more constant effective levels. The crucial advantage for all of us is that no surgery is required to insert the subcutaneous cannula. This less invasive treatment option is a huge relief for all of us.

Parkinson's Patients in Hospital: The Challenges and Solutions

The increased risk of melanoma in Parkinson's patients has been documented in numerous scientific studies. A first comprehensive meta-analysis was published by Liu and colleagues in the journal Neurology in 2011 and found that people with Parkinson's had more than double the risk of being diagnosed with melanoma. An important study on this topic was also published in 2010 by John Bertoni and colleagues in the Archives of Neurology (later renamed JAMA Neurology). The Bertoni study used data from the North American Parkinson's and Melanoma Survey Group and found that the incidence of malignant melanoma was 2,24 times higher in the Parkinson's cohort compared to the general population.